Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Danaher Corp.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Emmanuel Ligner, president and CEO of Cytiva, talks to In Vivo about how the company will dramatically increase its manufacturing capabilities over the next five years, at a price tag of $500m.
While the main role of SARS-CoV-2 antibody testing is currently limited to determining exposure to the virus in populations, the scientific community is working hard to define the neutralizing properties of the antibodies detected, and the duration of the immune response. As a result, antibody testing could be here to stay for the long term for monitoring populations, testing vaccines and selecting patients for trials of a variety of new therapies to treat numerous conditions.
In 2019, more than 75% of the biological therapies approved by the FDA used technologies developed by GE Healthcare Life Sciences for manufacturing. Following the completion of a $21.9bn acquisition by Danaher, the company has rebranded to Cytiva. In Vivo speaks with CEO Emmanuel Ligner to learn more about his vision for the new company and the impact of COVID-19.
- In Vitro Diagnostics
- Medical Devices
- Research, Analytical Equipment & Supplies
- Other Names / Subsidiaries
- Beckman Coulter
- GE Life Sciences
- Pall Corporation
- Radiometer Medical ApS
- HemoCue AB
- Integrated DNA Technologies, Inc.
- Leica Microsystems Inc.
- Leica Biosystems Inc.
- Vision Systems Ltd.
- Coretech Holdings, LLC
- Q3DM Inc.